INS and Obesity: Thirteen out of thirty-one (41.9%) patients presented with the following comorbidities: hypertension (n = 3, 9.6%; treated with calcium channel blockers and beta-blockers), obesity (n = 3, 9.6%), type 2 diabetes mellitus (n = 2, 6.4%; treated with insulin therapy), thyroiditis (n = 2, 6.4%; treated with levothyroxine), allergic rhinitis (n = 2, 6.4%, in clinical remission), and chronic obstructive pulmonary disease (n = 1, 3.2%; treated with inhaled corticosteroids and bronchodilators).